Why Contract Research Organizations Are So Hot

ByConnor Hodde

With more drugmakers outsourcing more trials to contract research organizations, few should be surprised that the CRO sector is generating investor interest. The attention-grabbing deal announced this week in which two private equity firms – Carlyle Group and Hellman & Friedman – agreed to pay $3.9 billion in cash to buy Pharmaceutical Product Development is no random bet.

http://www.forbes.com/sites/edsilverman/2011/10/04/why-contract-research-organizations-are-so-hot/

Similar Posts

Optic Nerve Regeneration in Mice Linked to Improved Vision

ByConnor Hodde

Interventions resulting in optic nerve regeneration restored some components of vision, according to the results of a mouse model study published online May 21 issue of the Proceedings of the National Academy of Sciences. If these findings are confirmed and extended to other models, they may ultimately offer promise to patients with glaucoma or optic…

Aging of Eyes Is Blamed for Range of Health Woes

ByConnor Hodde

For decades, scientists have looked for explanations as to why certain conditions occur with age, among them memory loss, slower reaction time, insomnia and even depression. They have scrupulously investigated such suspects as high cholesterol, obesity, heart disease and an inactive lifestyle. Now a fascinating body of research supports a largely unrecognized culprit: the aging…

EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration

ByConnor Hodde

“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release

Retina Protein That May Help Conquer Blindness Discovered

ByConnor Hodde

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. The research reveals events that may…

SOCS3 in retinal neurons and glial cells suppresses VEGF signaling to prevent pathological neovascular growth

ByConnor Hodde

Neurons and glial cells in the retina contribute to neovascularization, or the formation of abnormal new blood vessels, in proliferative retinopathy, a condition that can lead to vision loss or blindness. We identified a mechanism by which suppressor of cytokine signaling 3 (SOCS3) in neurons and glial cells prevents neovascularization. We found that Socs3 expression…

Brolucizumab as Good as Aflibercept for Neovascular AMD

ByConnor Hodde

Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials. Earlier this month, Novartis announced that the U.S. Food and Drug Administration accepted the company’s brolucizumab application for the treatment of nAMD. Reductions in central subfield thickness (CST) on optical coherence…